Clinical trials: MAB
Pregnancy Related, Immune-mediated Diseases
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development
What is this project about? This project aims to better understand how the immune system develops in babies whose mothers received immunomodulatory treatments during pregnancy.
- Trial name
- NEWbornIMMPACT (NCT07033663)
- Testing
- Monoclonal antibody
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundació Sant Joan de Déu
Rectal Cancer
Preoperative Panitumumab and Radiotherapy in Rectal Cancer
The purpose of this study is to investigate the activity of panitumumab in combination with standard preoperative radiotherapy in locally advanced rectal cancer, followed by complete surgery and adjuvant chemotherapy.
- Trial name
- PrePaRad (NCT00973193)
- Testing
- panitumumab
- Where
- 8 sites in Belgium
- Volunteers
- 20 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Neoplasms
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
The Primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers…
- Trial name
- NCT02908906
- Testing
- JNJ-63723283
- Where
- 20 sites in United States, Moldova and 5 more
- Volunteers
- 234 people
- Sponsor
- Janssen Research & Development, LLC
Coronavirus Disease 2019 COVID-19
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and…
- Trial name
- NCT04341116
- Testing
- TJ003234
- Where
- 14 sites in United States
- Volunteers
- 149 people
- Sponsor
- I-Mab Biopharma US Limited
Dermatitis, Atopic
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the safety and pharmacokinetic of 611 in Chinese children and adolescents with moderate to severe atopic dermatitis.
- Trial name
- NCT06324812
- Testing
- Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Colorectal Neoplasms, Colorectal Carcinoma
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line therapy.
- Conditions
- Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Cancer Metastatic, Neoplasm Metastasis
- Trial name
- OPALO (NCT03142516)
- Testing
- Panitumumab, Irinotecan, Folinic acid
- Where
- 12 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Nontuberculous Mycobacterial Pulmonary Infection
PK and PD of Antibiotics for Treatment of Mycobacterium Abscessus Pulmonary Disease
Investigating the PK and PD indices in patients with M. abscessus complex-PD who will be treated with a currently recommended regimen, minimum inhibitory concentrations of organism, and their relation with clinical outcomes
- Trial name
- NCT05676138
- Testing
- Measuring PK and PD indices in patients who receive conventional treatment
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Inhalational Anthrax
Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin
- Trial name
- NCT01952444
- Testing
- ETI-204, Ciprofloxacin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Elusys Therapeutics
Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing…
- Trial name
- MagnetisMM-7 (NCT05317416)
- Testing
- Elranatamab, Lenalidomide
- Where
- 209 sites in United States, Australia and 25 more
- Volunteers
- 854 people
- Sponsor
- Pfizer
Prevention of Chikungunya Virus Infection
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of mRNA-1944 in healthy adult subjects.
- Trial name
- NCT03829384
- Testing
- mRNA-1944
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Lymphoma
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing…
- Trial name
- NCT00006721
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 259 sites in United States
- Volunteers
- 571 people
- Sponsor
- SWOG Cancer Research Network
Thrombocytopenia, Immune Thrombocytopenia
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis.
- Conditions
- Thrombocytopenia, Immune Thrombocytopenia, Myelodysplasia
- Trial name
- APAT (NCT04800458)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 225 people
- Sponsor
- University Hospital, Bordeaux
Ovarian Cancer
The Effect of TRA-8 on Ovarian Cancer Tissue
The goal of this study is to determine the apoptosis-inducing efficacy of TRA-8 in patient ovarian cancer tissues using a tissue slice technology.
- Trial name
- NCT00711932
- Where
- United States
- Volunteers
- 478 people
- Sponsor
- University of Alabama at Birmingham
Paroxysmal Nocturnal Hemoglobinuria
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
The objective of this study was to assess the long-term safety and efficacy of eculizumab in hemolytic PNH patients who completed the 4-week screening and 12-week treatment period of the C07-001 study.
- Trial name
- NCT01194804
- Testing
- Eculizumab
- Volunteers
- 27 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
End-Stage Kidney Disease (ESKD)
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard…
- Trial name
- NCT07759167
- Testing
- REGN9933, REGN7508, REGN9533
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
RATIONALE: Monoclonal antibodies such as anti-cytotoxic T-lymphocyte-associated antigen-4 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00047164
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Crohn Disease
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy and safety of ustekinumab in Chinese participants with moderately to severely active Crohn's disease.
- Trial name
- NCT05029921
- Testing
- Ustekinumab
- Where
- 29 sites in China
- Volunteers
- 182 people
- Sponsor
- Janssen Research & Development, LLC
Dermatitis, Atopic, Eczema, Atopic
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination…
- Trial name
- NCT06554847
- Testing
- 611, Topical corticosteroid
- Where
- 3 sites in China
- Volunteers
- 417 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
COVID-19
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-4 (NCT04634409)
- Testing
- Bamlanivimab, Etesevimab, VIR-7831
- Where
- 141 sites in United States, Argentina and 1 more
- Volunteers
- 1,755 people
- Sponsor
- Eli Lilly and Company
Coronavirus Infections
Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
Study hypothesis: the viral neutralizing monoclonal antibodies Tiksagevimab/Cilgavimab and Regdanvimab have high neutralizing activity against SARS-CoV-2 coronavirus, including Omicron strain, and may be effective in treating…
- Trial name
- NCT05982704
- Testing
- tixagevimab/cilgavimab 150+150 mg, tixagevimab/cilgavimab 300+300 mg, regdanvimab
- Where
- Russia
- Volunteers
- 82 people
- Sponsor
- City Clinical Hospital No.52 of Moscow Healthcare Department
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.